جستجوی مقالات مرتبط با کلیدواژه "bloating" در نشریات گروه "پزشکی"

   Bloating, a biological process characterized by gas accumulation within the gastrointestinal tract, often results in abdominal pain and discomfort. Both children and adults frequently experience bloating and associated abdominal pain, causing significant distress. This review aims to identify and report on natural antioxidants that may be effective in alleviating bloating.

  For this review, literature searches were conducted using keywords such as "herbal remedies," "bloating," and "traditional medicine." Databases such as Google Scholar, SID, MagIran, PubMed, and Scopus were utilized for the search. Ethnobotanical articles relevant to the topic were reviewed.

Herbal remedies including ginger, peppermint, turmeric, cumin, caraway, wormwood, dandelion, burdock, hibiscus, lemon balm, chamomile, and fennel have been shown to effectively reduce abdominal bloating and improve digestive health.

  The present study demonstrates that Iranian herbal remedies with potent antioxidant properties offer effective solutions for reducing abdominal bloating and enhancing digestive health. These herbs, through their bioactive compounds, not only alleviate gas accumulation within the stomach and intestines but also exert anti-inflammatory and soothing effects, which contribute to the alleviation of bloating-related abdominal pain. These findings emphasize the significance of utilizing natural and traditional treatments for managing digestive disorders and improving quality of life. A combination of these herbs, considering their unique properties, appears to be a comprehensive and effective therapeutic strategy for reducing bloating and promoting gastrointestinal health.

Irritable bowel syndrome (IBS) is the most frequent functional gastrointestinal (GI) disorder. In this study, we aimed to evaluate the different aspects of IBS among Middle Eastern residents.

During the study period, patients attending gastroenterology clinics of nine tertiary referral centers in four Middle Eastern couturiers (Iran, Egypt, Kuwait, and Turkey) were evaluated by Rome IV diagnostic criteria, and those who fulfilled the diagnostic criteria of IBS were asked to fill in a questionnaire covering different demographics and clinical aspects.

Overall, during a 6-month period, 509 patients with IBS were included. 41.3% of the participants were male (210 patients), and 37.4% of them had academic education. 50% of the participants were Caucasian, and 34% were Arab, and originally, they were citizens of 18 countries. 77.4% of the participants were residents of subtropical areas, while 22.2% were living in temperate regions. The average age of the participants during the first presentation in subtropical and temperate areas were 38.4 ± 12.19 and 38.06 ± 12.18 years, respectively (P = 0.726). The most common subtypes of IBS in subtropical areas were unclassified (IBS-U, 44.4%), constipation dominant (IBS-C, 27.6%), mixed pattern (IBS-M, 21%), and diarrhea dominant (IBS-D, 6.8%) in descending order while in temperate areas the most common subtypes were IBS-U (43.3%), and IBS-D (22.1%), respectively (P < 0.001). Besides abdominal pain, the most common symptom of patients in each region was bloating (62.2% and 68.1%, respectively, P = 0.246). The rate of depression and anxiety were significantly higher among the residents of temperate areas in comparison with subtropical regions (41.6% vs. 16.5% and 80.5% vs. 58.4%, respectively, P < 0.001).

Although the average age of IBS presentation is the same in subtropical and temperate areas, it seems that in temperate areas, the rate of IBS-D is more prevalent than in subtropical regions. The rate of anxiety and depression are significantly higher among those who searched social media and the internet to get information about their problems.

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder that causes abdominal pain, distension, change of bowel habit, bloating, constipation, diarrhea, and mucus discharge along with stools. Although the disease causes long-term and agonizing pain, no ideal cure has been found for it so far. This study aimed to investigate the efficacy and compliance of Mentha aquatica L. extract for the treatment of bloating caused by IBS. This double-blind, randomized, placebo-controlled trial study was conducted in Tooba gastroenterology clinic in Sari, Iran, during 2019 (from January to May). A total of 104 patients with IBS in the age range of 20-80 years were randomly divided into two parallel groups of herbal medicine (MAC-330) and placebo. Study period consisted of a 4 weeks of administration, and 2 weeks of follow-up. IBS-associated symptoms including severity of bloating (as primary outcome) and frequency of defecation and abdominal pain were evaluated using a questionnaire before treatment, 1, 2 and 4 weeks after beginning treatment and 2 weeks after stopping treatment. There were no significant differences between the two groups in terms of their baseline characteristics (p > 0.05). The severity of bloating was significantly reduced in the both groups at fourth week (p < 0.030) and 2 weeks after stopping intervention (sixth week) (p < 0.026). The frequency of defecation has increased with the onset of the intervention until the fourth week of the treatment which was not significant. The abdominal pain reduced during the 4 weeks’ intervention, but it was not significant. Based on the obtained results, MAC-330 could not be used as an effective treatment for patients with IBS in short time; however, it reduces the abdominal bloating and pain in these patients, especially in the long-term use.

Irritable bowel syndrome (IBS) is a chronic functional disorder of the gastrointestinal tract that causes abdominal pain or discomfort and alters bowel with no organic abnormalities. Treatment options for IBS have increased in number in the past decade, and clinicians should not be limited to use only conventional treatments to cure it. This article is a placebo‑controlled clinical trial to assess the therapeutic effects of low‑dose bismuth subcitrate on symptoms and the health‑related quality of life in adult patients with IBS.

This clinical trial was done during July 2015 to January 2016 in Isfahan, Iran. For each of three subtypes (IBS‑constipation dominant, IBS‑diarrhea dominant [IBS‑D], and IBS‑mixed), we included patients with IBS aged 18–70 years, diagnosed according to the Rome III criteria. In this study, 129 eligible patients were enrolled, of which 119 continued on the protocol to the end of study. They were allocated in placebo group (Group A) and intervention group (Group B). The medication for Group B was mebeverine and bismuth subcitrate and for Group A was mebeverine and placebo of bismuth subcitrate. Initially, the patients of both groups completed IBS‑related questionnaires (IBS‑quality of life, IBS‑severity scoring system), then given drugs for a 4‑week period (1st on‑drug period). Then, both groups were given only mebeverine hydrochloride 200 mg capsule for another 4 weeks (off‑drug period). At last, Group A and Group B were given medication (2nd on‑drug period), the same as 1st on‑drug period.

With respect to quality of life, the trend of IBS‑QOL score changed significantly during the study period in both the intervention and placebo groups; however, no significant differences were observed between the two groups (P < 0.005). In subgroups analysis, quality of life significantly improved in IBS‑D during the study from the first measurement to the end of study (P = 0.004). The trends of changes in the severity of pain during the study between the intervention and control group were significantly different (P = 0.018).

According to our study, IBS‑D patients’ symptoms improved significantly with bismuth therapy. We found that adding low‑dose bismuth to mebeverine in nonresponsive IBS patients in conventional treatment could be helpful.

The current study aimed to evaluate the efficacy of mesalazine plus bismuth on patients with irritable bowel syndrome (IBS) and chief complaint of bloating..
The current quasi-experimental study, included patients with IBS and chief complaint of bloating and incomplete defecation. They were treated with masalazine and bismuth subcitrate and followed regularly based on monthly visits. The rate of symptoms relief, patient's satisfaction and any side effects were recorded during the surveillance..
Overall, 42 patients (33 females and 9 males) were included. The mean age of the patients was 35.9 years (ranged 22 - 67 years); 32%, 44% and 24% had high, medium and low socioeconomic levels, respectively; 96% of the patients were nonsmokers and just two patients had a history of alcohol consumption. Two patients had glucose intolerance, four had hypothyroidism and four had past history of valvular heart disease. In 20% of the patients, the family history for intestinal bowl disease (IBD) was positive. Ten patients had a history of bloody diarrhea and no one had a history of any significant liver diseases. The most common symptoms of patients included incomplete defecation and tenesmus (41 patients, 97.6%), bloating (39 patients, 92.8%), abdominal fullness (35 patients, 83.3%) and mucus discharge (30 patients, 71.4%). After an average six months of treatment (3 - 11 months), 69.1% of patients reported improvement of symptoms more than 50% (38.1%, ranged 75% - 100%), and 31% (ranged 50% - 75%) indicated overall symptoms relief). The most significant improvement was reported for bloating (85%). There were no major side effects except minor degrees of diarrhea among 26% of the subjects..
The results of the study were indicative of improvement and symptom relief in the majority of patients and it seems that treatment prolongation up to six months could be a key factor to achieve better clinical responses. It is recommended that further randomized clinical trials evaluate this therapeutic regimen..

Irritable bowel syndrome (IBS) is a common disorder in Iran with challenging treatment. Although trials have suggested that probiotics alleviate the complaints of patients with minimal side effects, they have not been investigated in Iranian adults. In a randomized double-blind study, 108 eligible IBS patients (Rome III Criteria) aged 20 – 70 years who referred consecutively to a clinical center in Tehran with abdominal bloating from 2010 to 2012 received a combination probiotics or placebo twice daily for 4 weeks. The objective was to evaluate the efficacy and safety of a multi-strain probiotics combination. One week prior to and throughout the treatment, the participants recorded their abdominal symptoms on a daily basis, using visual analogue scale and reported satisfactory relief of general symptoms at the end of each week. Adverse events were evaluated by self-reporting and physical examination. Continuous variables were analyzed by independent t-test and chi-square was used for binomials. The baseline characteristics were balanced (60% female, mean age 36.7 ± 11.5). A total of 97 (51 intervention, 46 control) completed the treatment. Intention to treat analysis was done on 108 allocated subjects. 85% of the probiotic group reported satisfactory relief of general symptoms compared with 47% in the control group (P < 0.01). A reduction in abdominal bloating and pain with probiotic was superior to placebo [-13.0 vs. -3.7 (P < 0.01), -8.2 vs. -2.1 (P = 0.02), respectively]. No severe adverse drug reaction was seen in either group. A 4-week period of treatment with the combination probiotics twice daily was safe, well tolerated, and effective in our patients. Further investigation is recommended for other subgroups of IBS.